Skip to main content

Table 3 Stratified analyses for modification effect on the association between level of week-1 haemoglobin and one-year mortality among the 3,440 subjects in the PSM cohort

From: Anaemia in the first week may be associated with long-term mortality among critically ill patients: propensity score-based analyses

Variables

Subgroup

Number of patients

Events (death)

HR ratio (95%CI)

p value

p for interaction

Age (years)

     

0.586

 

< 65

1388

612

1.367 (1.164–1.605)

< 0.001

 
 

≥ 65

2086

1026

1.325 (1.172–1.498)

< 0.001

 

Sex

     

0.168

 

Female

1304

531

1.210 (1.020–1.435)

0.028

 
 

Male

2170

1107

1.415 (1.256–1.593)

< 0.001

 

Renal disease

     

0.588

 

No

2586

1268

1.328 (1.189–1.483)

< 0.001

 
 

Yes

888

370

1.433 (1.163–1.765)

0.001

 

COPD

     

0.167

 

No

3258

1531

1.361 (1.230–1.506)

< 0.001

 
 

Yes

216

107

1.031 (0.705–1.508)

0.877

 

Lymphoma/leukaemia

     

0.575

 

No

3287

1513

1.316 (1.189–1.456)

< 0.001

 
 

Yes

187

125

1.420 (0.985–2.048)

0.060

 

Moderate or severe liver disease

     

0.004

 

No

3304

1519

1.361 (1.230–1.506)

< 0.001

 
 

Yes

170

119

0.806 (0.560–1.159)

0.245

 

APACHE II score*

     

0.765

 

≤ 23.00

737

275

1.388 (1.095–1.760)

0.007

 
 

> 23.00

2737

1363

1.315 (1.182–1.463)

< 0.001

 

Blood transfusion

     

0.248

 

No

1766

688

1.219 (1.039–1.429)

0.015

 
 

Yes

1708

950

1.082 (0.939–1.246)

0.275

 

Platelet (103/µL)*

     

0.128

 

< 173.8

1737

990

1.359 (1.197–1.542)

< 0.001

 
 

≥ 173.8

1737

648

1.187 (1.017–1.384)

0.029

 

Blood urea nitrogen (mg/dL)*

     

0.799

 

< 27.0

1707

691

1.326 (1.142–1.540)

< 0.001

 
 

≥ 27.0

1767

947

1.279 (1.124–1.455)

< 0.001

 

Creatinine (mg/dL)*

     

0.699

 

< 1.2

1660

700

1.289 (1.111–1.494)

0.001

 
 

≥ 1.2

1814

938

1.305 (1.145–1.486)

< 0.001

 
  1. *Stratified by median level. COPD, chronic obstructive pulmonary disease; APACHE, acute physiology and chronic health evaluation.